Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.
Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.
Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.
Natera, Inc. (NASDAQ: NTRA) presented new data on its Signatera test at the American Association for Cancer Research (AACR) meeting from April 14-19, 2023. The studies included findings on personalized MRD testing in various cancers, such as muscle-invasive bladder cancer and colorectal cancer. Key highlights include:
- Prediction of tumor response and recurrence using ctDNA in patients with esophago-gastric carcinoma and MIBC.
- Genomic profiling of more than 13,000 patients with colorectal cancer.
- ctDNA's potential to guide imaging-based surveillance for post-surgery patients.
- Data supporting ctDNA's role as a predictive biomarker in hepatocellular carcinoma.
These presentations emphasize Natera's commitment to advancing cancer care through innovative testing solutions.
Natera, Inc. (NASDAQ: NTRA) announced a study published in Cancer demonstrating the prognostic and predictive utility of its Signatera test for patients with stages III-IV melanoma. The study analyzed 555 plasma samples from 69 patients and revealed that MRD positivity post-surgery was linked to shorter distant metastasis-free survival (HR=10.77; p=0.01) and earlier detection of recurrence. Among unresectable patients, increasing ctDNA levels indicated shorter progression-free survival (HR=22; p=0.006). Signatera's accuracy in monitoring treatment response highlights its potential for personalized therapy decisions, addressing the unmet need for diagnostic tools in melanoma management.
Natera, Inc. (NASDAQ: NTRA) has announced significant advancements in commercial coverage for its Signatera molecular residual disease test. Effective March 1, 2023, Blue Shield of California will cover Signatera for all solid tumor patients, marking the company's first pan-cancer policy. Additionally, as of January 1, 2023, Blue Cross and Blue Shield of Louisiana will provide coverage for colorectal and bladder cancer monitoring. This underscores the medical necessity and enhanced access to Signatera testing, which has been validated through approximately 40 peer-reviewed publications for its efficacy in detecting cancer recurrence earlier than traditional methods.
Natera, Inc. (NASDAQ: NTRA) reported a robust performance for Q4 2022, achieving total revenues of $217.3 million, a 25.6% increase from Q4 2021. For the full year 2022, revenues reached $820.2 million, marking a 31.1% growth. The company processed approximately 559,700 tests in Q4 2022, up by 27.6% year-over-year, and over 2 million tests for the year, a 31.6% rise. However, gross margins declined to 41.4% in Q4 2022 from 45.6% in Q4 2021 due to higher costs. Looking ahead, Natera expects 2023 revenues between $980 million and $1 billion and aims to reduce cash burn by approximately $150 million.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
